Please assess the completion status of the following clinical trial:

Trial Title: Mechanisms of Sleep Disruption Hyperalgesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy~* Age 18-48~* Meets Research Diagnostic Criteria for Normal Sleepers~* Stable sleep phase within 21:00 and 08:00~* Total sleep time between 6.5 and 8.5 hours per night~* Sleep efficiency ≥85%~* Epworth Sleepiness Scale Score \<10~* Non-smoker/non-nicotine users~* Low Caffeine Users (≤2 cups per day)~Exclusion Criteria:~* Body Mass Index ≥35~* Lifetime history of chronic pain (\>6 months)~* Acute pain~* Significant medical or psychiatric morbidity within 6 months~* Lifetime history of bipolar disorder, psychotic disorder, serious recurrent major depression, serious post-traumatic stress disorder, or seizure disorder~* Respiratory, hepatic, renal, or cardiac conditions that would contraindicate opioid use~* Lifetime history of alcohol or substance abuse or dependence~* Lifetime history of opioid use \>36 doses or \>7 days of consecutive use~* Prior adverse reaction to general anesthetics, opioids, or capsaicin~* Clinically significant abnormal complete blood count or comprehensive metabolic profile~* Positive toxicology screen for opioids or recreational drugs~* Pregnant or lactating women~* Significant pre-admission psychological distress (T-scores \>64 on the Brief Symptom Inventory Global Scales)~* Significant lifetime history of serious head injury that is determined to influence pain processing or sleep systems

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 48 Years
- Healthy Volunteers: t

Study Arms:
- Morphine US then Morphine FA (Type: EXPERIMENTAL): Participants randomized to receive Morphine and the Uninterrupted Sleep (US) condition first. After a polysomnography (PSG) screening night, participants were randomized to receive two consecutive nights of uninterrupted sleep (US). With a minimum of a two week washout period, participants then completed the opposing sleep condition of two nights of forced awakenings (FA). They will receive the Morphine injection (0.08mg/kg) via IV bolus over 30 seconds during each experimental quantitative sensory testing session that occurs after the US and FA sleep conditions are completed.
- Placebo US then Placebo FA (Type: PLACEBO_COMPARATOR): Participants randomized to receive the saline placebo and the Uninterrupted Sleep (US) condition first. After a polysomnography (PSG) screening night, participants were randomized to receive two consecutive nights of uninterrupted sleep (US). With a minimum of a two week washout period, participants then completed the opposing sleep condition of two nights of forced awakenings (FA). They will receive the injection via IV bolus over 30 seconds during each experimental quantitative sensory testing session that occurs after the US and FA sleep conditions are completed.
- Morphine FA then Morphine US (Type: EXPERIMENTAL): Participants randomized to receive Morphine and the Forced Awakenings (FA) condition first. After a polysomnography (PSG) screening night, participants were randomized to receive two consecutive nights of forced awakenings (FA). With a minimum of a two week washout period, participants then completed the opposing sleep condition of two nights of uninterrupted sleep (US). They will receive the Morphine injection (0.08mg/kg) via IV bolus over 30 seconds during each experimental quantitative sensory testing session that occurs after the FA and US sleep conditions are completed.
- Placebo FA then Placebo US (Type: PLACEBO_COMPARATOR): Participants randomized to receive the saline placebo and the Forced Awakenings (FA) condition first. After a polysomnography (PSG) screening night, participants were randomized to receive two consecutive nights of forced awakenings (FA). With a minimum of a two week washout period, participants then completed the opposing sleep condition of two nights of uninterrupted sleep (US). They will receive the injection via IV bolus over 30 seconds during each experimental quantitative sensory testing session that occurs after the FA and US sleep conditions are completed.

Based on this trial design, predict the completion outcome and termination type (if applicable).